Jon Amund Eriksen

2.4k citations

32 papers · 2.0k indexed · h-index 22

Immunology top 2%
- Immunotherapy and Immune Responses 16
- T-cell and B-cell Immunology 4
Oncology top 5%
- Cancer Immunotherapy and Biomarkers 12
Energy Engineering and Power Technology top 5%
Gastroenterology top 5%
Biotechnology top 5%
- Cancer Research and Treatments 3
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 6
Pathology and Forensic Medicine
- Genetic factors in colorectal cancer 4
Materials Chemistry
- Hydrogen Storage and Materials 4
Molecular Biology
- Chemical Synthesis and Analysis 3

Co-authors: Gustav Gaudernack Mona Møller Marianne Klemp Erik Thorsby Trond Buanes Tobias Gedde‐Dahl Ivar P. Gladhaug Ingvil Sæterdal
Cited by: Immunology Oncology Energy Engineering and Power Technology
Journals: Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (1 paper)Journal of Clinical Oncology (3 papers)
Partner nations: Norway United Kingdom Germany

In The Last Decade

Jon Amund Eriksen

30 papers receiving 1.9k citations

Peers

Countries citing papers authored by Jon Amund Eriksen

Since Specialization

Citations

This map shows the geographic impact of Jon Amund Eriksen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Amund Eriksen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Amund Eriksen more than expected).

Fields of papers citing papers by Jon Amund Eriksen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Amund Eriksen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Amund Eriksen. The network helps show where Jon Amund Eriksen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jon Amund Eriksen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jon Amund Eriksen Line = papers co-authored together Jon Amund Eriksen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study Cancer Immunology Immunotherapy ·Else-Marit Inderberg-Suso,Nand Singh,Robert M. Miller,Sarah Arbe‐Barnes,Henrik K. Eriksen,Berit lversen,Hedvig Vidarsdotter Juul,Jon Amund Eriksen,Karianne Risberg Handeland	2025	0
2	A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer Heliyon ·Sara Roth,Kasmira Wilson,Robert G. Ramsay,Catherine Mitchell,Shienny Sampurno,Toàn Pham,Joseph C. Kong,Stephen Q. Wong,Alexander G. Heriot,Sanjeev Deva,Matthew Burge,Cecilie Sverdrup,Anne‐Sophie W. Møller,Łukasz Kuryk,Jon Amund Eriksen,Magnus Jäderberg,John Zalcberg,Michael Michael	2024	2
3	HYDRIDE4MOBILITY: An EU HORIZON 2020 project on hydrogen powered fuel cell utility vehicles using metal hydrides in hydrogen storage and refuelling systems International Journal of Hydrogen Energy ·V.A. Yartys,Mykhaylo Lototskyy,Vladimir Linkov,Sivakumar Pasupathi,Moegamat Wafeeq Davids,Ivan Tolj,Gojmir Radica,R.V. Denys,Jon Amund Eriksen,K. Taube,José M. Bellosta von Colbe,Giovanni Capurso,Martin Dornheim,Fahmida Smith,Delisile Mathebula,Dana Swanepoel,Suwarno Suwarno	2021	50
4	TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial British Journal of Cancer ·Daniel H. Palmer,Juan W. Valle,Yuk Ting,Olusola Olusesan Faluyi,John P. Neoptolemos,Trine Jensen Gjertsen,Berit Iversen,Jon Amund Eriksen,Anne-Sophie Møller,Anne-Kirsti Aksnes,Robert C. Miller,Svein Dueland	2020	49
5	An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer Annals of Oncology ·Jon Amund Eriksen,I P Gladhaug,Arne R. Rosseland,Karianne Risberg Handeland,Trond Buanes	2017	5
6	Vaccination of patients with cutaneous melanoma with telomerase-specific peptides Cancer Immunology Immunotherapy ·Robert E. Hunger,Kristin Lang,Carrie J. Markowski,Sissel Trachsel,Mona Møller,Jon Amund Eriksen,Anne‐Marie Rasmussen,Lasse R. Braathen,Gustav Gaudernack	2011	47
7	Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras International Journal of Cancer ·Synne Wedén,Marianne Klemp,Ivar P. Gladhaug,Mona Møller,Jon Amund Eriksen,Gustav Gaudernack,Trond Buanes	2010	137
8	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study British Journal of Cancer ·Stephan Bernhardt,(unknown),Dagmar S. Trachsel,Mona Møller,Jon Amund Eriksen,Maria Lettisia Meo,Trond Buanes,Gustav Gaudernack	2006	238
9	Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer Cancer Immunology Immunotherapy ·Paal Brunsvig,Steinar Aamdal,Marianne Klemp,Gunnar Kvalheim,C. J. Markowski-Grimsrud,I. Sve,Marianne Dyrhaug,Sissel Trachsel,Mona Møller,Jon Amund Eriksen,Gustav Gaudernack	2006	196
10	Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM‐CSF as adjuvant Experimental Dermatology ·Robert E. Hunger,C.U. Brand,Michael Streit,Jon Amund Eriksen,(unknown),Ingvil Sæterdal,Lasse R. Braathen,Gustav Gaudernack	2001	33
11	A TGFβRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cells Cancer Immunology Immunotherapy ·Ingvil Sæterdal,Marianne Klemp,Per thor Straten,Jon Amund Eriksen,Gustav Gaudernack	2001	61
12	Selection of a cyclic nonapeptide inhibitor to α-chymotrypsin using a phage display peptide library Molecular Diversity ·Margareta Krook,Christer Lindbladh,Jon Amund Eriksen,Klaus Mosbach	1997	22
13	Identification of a putative motif for binding of peptides to HLA-DQ2 International Immunology ·Bente H. Johansen,Frode Vartdal,Jon Amund Eriksen,Erik Thorsby,Ludvig M. Sollid	1996	73
14	Selection of peptides with surface affinity for α-chymotrypsin using a phage display library Journal of Chromatography A ·Margareta Krook,Christer Lindbladh,Staffan Birnbaum,Hilde Merete Naess,Jon Amund Eriksen,Klaus Mosbach	1995	15
15	Binding of peptides to HLA-DQ molecules: peptide binding properties of the disease-associated HLA-DQ(α1^0501, β1^0201) molecule International Immunology ·Bente H. Johansen,Søren Buus,Frode Vartda,Helge Vlken,Jon Amund Eriksen,Erik Thorsby,Ludvlg M. Sollid	1994	40
16	p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4⁺ and CD8⁺ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp) International Journal of Cancer ·Beate Fossum,Tobias Gedde‐Dahl,Jarle Breivik,Jon Amund Eriksen,Anne Spurkland,Erik Thorsby,Gustav Gaudernack	1994	70
17	Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cells European Journal of Immunology ·Beate Fossum,Tobias Gedde‐Dahl,Torbjern Hansen,Jon Amund Eriksen,Erik Thorsby And,Gustav Gaudernack	1993	50
18	T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restriction European Journal of Immunology ·Tobias Gedde‐Dahl,Beate Fossum,Jon Amund Eriksen,Erik Thorsby,Gustav Gaudernack	1993	46
19	Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gin → Leu61) International Immunology ·Tobias Gedde‐Dahl,Anne Spurkland,Jon Amund Eriksen,Erik Thorsby,Gustav Gaudernack	1992	53
20	T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides Human Immunology ·Tobias Gedde‐Dahl,Jon Amund Eriksen,Erik Thorsby,Gustav Gaudernack	1992	51

About Jon Amund Eriksen

Jon Amund Eriksen is a scholar working on Immunology, Oncology and Biotechnology, having authored 32 papers that have together received 2.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (16 papers), Cancer Immunotherapy and Biomarkers (12 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Genetic factors in colorectal cancer (4 papers), Hydrogen Storage and Materials (4 papers), T-cell and B-cell Immunology (4 papers), Chemical Synthesis and Analysis (3 papers) and Cancer Research and Treatments (3 papers). The work is most often cited by research in Immunology (965 citations), Oncology (979 citations) and Energy Engineering and Power Technology (99 citations). Jon Amund Eriksen has collaborated with scholars based in Norway, United Kingdom and Germany. Frequent co-authors include Gustav Gaudernack, Mona Møller, Marianne Klemp, Erik Thorsby, Trond Buanes, Tobias Gedde‐Dahl, Ivar P. Gladhaug, Ingvil Sæterdal, Stephan Bernhardt and Dagmar S. Trachsel. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact